Dodd, Lori E <br/><br/>
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Aug 2008 
 - 3791-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.16.1711  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Bias<br/>Clinical Trials, Phase III as Topic--economics<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Humans<br/>Neoplasms--drug therapy<br/>Randomized Controlled Trials as Topic--economics<br/>Reproducibility of Results<br/>Time Factors<br/>Treatment Outcome